The Shadow Market: How Unregulated 7-OH Is Fueling a New Public Health Crisis

NORTH CHARLESTON, SC – September 08, 2026 – On the shelf of a local gas station or smoke shop, nestled between energy drinks and snacks, sits a product that represents a troubling new frontier in the nation’s battle with substance abuse. Packaged in colorful wrappers as flavored gummies, potent shots, or dissolvable strips, these items are sold not as kratom, but under innocuous names like “7-OH,” “7-Hydroxy,” or “7-HMG.” They contain concentrated 7-hydroxymitragynine, a powerful opioid compound that is driving a surge in addiction and prompting urgent warnings from federal health officials.

This emerging crisis, born from a combination of market innovation and regulatory loopholes, has forced local governments onto the front lines. Here in North Charleston, city officials have launched a public awareness campaign to alert residents to the dangers of a substance that the U.S. Food and Drug Administration (FDA) has described as a “potent opioid product that has not been proven safe or effective for any use.” It’s a case study in how quickly unregulated markets can evolve, creating significant economic and social fallout that outpaces the federal government’s ability to respond.

A Legal Loophole Creates a Potent Threat

The substance at the center of the storm, 7-hydroxymitragynine, is an alkaloid found naturally in the leaves of the kratom tree. However, in its natural botanical form, it exists only in trace amounts. The products now proliferating online and in convenience stores are vastly different. They contain concentrated, and often synthetic, forms of 7-OH, creating a substance that some research suggests is up to 13 times more potent than morphine.

The global market for kratom extracts is booming, projected to grow from an estimated $244.7 million in 2026 to over half a billion dollars by 2033, with North America leading the growth. This economic incentive has fueled a wave of product innovation designed to maximize potency and appeal. By isolating and concentrating 7-OH, manufacturers have created a product that delivers a powerful opioid effect while existing in a regulatory gray area. Because these products are not marketed as traditional kratom, nor are they approved drugs or lawful dietary supplements, they have slipped through the cracks of federal oversight.

This ambiguity allows them to be sold openly in retail settings, often with deceptive packaging that masks their true nature. The FDA has warned that products promoted as “enhanced” or “spiked” kratom may contain substantially more 7-OH than would naturally occur. For parents, caregivers, and unsuspecting consumers, these items can look harmless, bearing more resemblance to candy or an energy supplement than a powerful opioid.

The Federal Response: A High-Stakes Game of Catch-Up

Federal agencies are now scrambling to address the threat. The FDA has been issuing warnings for years, citing a growing number of reports of adverse effects associated with 7-OH, including addiction, seizures, and severe withdrawal symptoms. In December 2025, the agency, in coordination with the Department of Justice, seized approximately $1 million worth of unlawful 7-OH products from firms in Missouri.

The regulatory wheels began turning more decisively this summer. On July 1, 2026, the U.S. Drug Enforcement Administration (DEA) announced its intent to temporarily place concentrated 7-OH and several related synthetic compounds into Schedule I of the Controlled Substances Act. This classification, the most restrictive category, is reserved for substances with a high potential for abuse and no accepted medical use, putting them in the same legal category as heroin and LSD.

However, this federal action highlights the “cat-and-mouse” game between regulators and manufacturers of novel psychoactive substances. The DEA’s proposed order specifically targets synthetic versions and products with elevated concentrations, carefully distinguishing them from botanical kratom. Furthermore, the time lag between the announcement of intent and the final order provides a window for manufacturers to adjust their formulas or dump existing inventory. As of early September, the DEA has successfully placed three semisynthetic kratom compounds into Schedule I, but the broader market remains a complex and shifting landscape.

In the absence of a comprehensive federal ban, several states, including North Dakota, Ohio, and Tennessee, have enacted their own restrictions. But the patchwork of state laws has done little to stem the tide of products available online and in states with fewer regulations, leaving communities to fend for themselves.

The Human Cost of an Unregulated Market

Beyond the headlines of regulatory battles, a devastating human toll is mounting. Addiction specialists and public health officials are witnessing a new wave of dependency driven by these easily accessible products. Many users begin with the belief that they are consuming a “natural” or “safe” alternative to pain medication or illicit opioids, only to find themselves trapped in a powerful addiction.

Personal accounts shared in online forums and with recovery specialists paint a grim picture. One individual who became addicted after being introduced to 7-OH shots at a local smoke shop described the experience as a rapid descent. “I went from thinking I found a harmless way to manage my anxiety to being completely dependent in a matter of weeks,” they wrote anonymously. “The withdrawal was a nightmare I wouldn’t wish on anyone.”

Reports from local health officials echo these concerns. In nearby Berkeley County, the coroner’s office linked two accidental overdose deaths in 2025 directly to kratom products purchased from gas stations. The experience of withdrawal is frequently described as being as severe, or even worse, than that of traditional opioids, with symptoms including debilitating anxiety, insomnia, severe gastrointestinal distress, and uncontrollable tremors. This leads to a cycle of compulsive use that can quickly result in financial ruin, job loss, and fractured relationships.

On the Front Lines: How Cities Are Fighting Back

With federal action lagging behind market innovation, the responsibility for public safety has fallen largely on local municipalities like the City of North Charleston. Led by Opioid Prevention Coordinator Shelby Joffrion, the city has launched a proactive campaign to educate residents and provide a lifeline for those struggling.

“Part of the concern is how these substances are sold and marketed,” the city’s official alert states, emphasizing that the products can be easy to overlook. The campaign urges residents to recognize the various forms of 7-OH, to look beyond the word “kratom” on packaging, and to talk openly with young people about the risks of substances purchased from convenience stores or online.

At the heart of North Charleston’s strategy is the Bridge2Hope app, a community resource developed to provide immediate access to help. The app connects residents with a network of local resources, including naloxone locations, 24/7 peer support through FAVOR Lowcountry, sober living facilities, and other treatment and recovery services. This innovative tool bypasses the often-confusing process of finding help by putting a directory of vetted, local support directly into the hands of those who need it most.

The city’s approach serves as a potential model for other communities grappling with the sudden influx of these dangerous products. By focusing on public awareness and leveraging technology to connect people with tangible resources, North Charleston is building a community-based defense against a threat that continues to proliferate in the aisles of everyday stores.

While federal agencies work to close the regulatory gaps that allowed this shadow market to flourish, the immediate battle is being fought by local leaders, healthcare providers, and community advocates. The accessibility of these products makes public awareness and direct-to-community resources like Bridge2Hope more critical than ever. As the market for novel psychoactive substances continues to evolve, the race to protect consumers from potent opioids hiding in plain sight is far from over.